Long-term results of combined preradiation chemotherapy and age-tailored radiotherapy doses for childhood medulloblastoma

Maura Massimino, Graziella Cefalo, Daria Riva, Veronica Biassoni, Filippo Spreafico, Emilia Pecori, Geraldina Poggi, Paola Collini, Bianca Pollo, Laura Valentini, Paolo Potepan, Ettore Seregni, Michela Casanova, Andrea Ferrari, Roberto Luksch, Daniela Polastri, Monica Terenziani, Federica Pallotti, Carlo Alfredo Clerici, Elisabetta SchiavelloFabio Simonetti, Cristina Meazza, Serena Catania, Marta Podda, Lorenza Gandola

Research output: Contribution to journalArticle

Abstract

To reduce the sequelae of craniospinal irradiation (CSI) in children under 10 (≥3) years old and to improve the prognosis for high-risk medulloblastoma in adolescents, we adjusted postoperative chemotherapy and CSI doses to patients' stage and age. From 1986 to 1995, 73 patients entered the study. Children under 10 and adolescents with metastases, residual disease (RD) or stage >T3 received postoperative IV vincristine and high-dose (HD) ± intrathecal (IT) methotrexate, while standard-risk adolescents were given IV vincristine and IT methotrexate. Chemotherapy was followed by CSI (19.8 Gy for children

Original languageEnglish
Pages (from-to)163-171
Number of pages9
JournalJournal of Neuro-Oncology
Volume108
Issue number1
DOIs
Publication statusPublished - May 2012

Keywords

  • Childhood medulloblastoma
  • High-dose methotrexate
  • Intrathecal chemotherapy
  • Reduced craniospinal radiotherapy

ASJC Scopus subject areas

  • Clinical Neurology
  • Cancer Research
  • Oncology
  • Neurology

Fingerprint Dive into the research topics of 'Long-term results of combined preradiation chemotherapy and age-tailored radiotherapy doses for childhood medulloblastoma'. Together they form a unique fingerprint.

Cite this